Galeterone for the treatment of advanced prostate cancer: the evidence to date

Diogo A Bastos1
Emmanuel S Antonarakis2
1Department of Oncology, Hospital Sirio-Libanes, Sao Paulo, Brazil; 2Department of Oncology and Urology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA

Correspondence: Emmanuel S Antonarakis
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, 1650 Orleans St, CRBI-IM45, Baltimore, MD, USA
Email eantona1@jhmi.edu

Abstract: Major advances have been achieved recently in the treatment of metastatic castration-resistant prostate cancer, resulting in significant improvements in quality of life and survival with the use of several new agents, including the next-generation androgen receptor (AR)-targeted drugs abiraterone and enzalutamide. However, virtually all patients will eventually progress on these therapies and most will ultimately die of treatment-refractory metastatic disease. Recently, several mechanisms of resistance to AR-directed therapies have been uncovered, including the AR splice variant 7 (AR-V7), which is a ligand-independent constitutionally-active form of the AR that has been associated with poor outcomes to abiraterone and enzalutamide. Galeterone, a potent anti-androgen with three modes of action (CYP17 lyase inhibition, AR antagonism, and AR degradation), is a novel agent under clinical development that could potentially target both full-length AR and aberrant AR, including AR-V7. In this manuscript, we will first discuss the biological mechanisms of action of galeterone and then review the safety and efficacy data from Phase I and II clinical studies of galeterone in patients with metastatic castration-resistant prostate cancer. A Phase III study of galeterone (compared against enzalutamide) in AR-V7-positive patients is currently underway, and represents the first pivotal trial using a biomarker-selection design in this disease.

Keywords: galeterone, AR splice variants, AR-V7, castration-resistant prostate cancer

Introduction

Despite significant recent advances in the treatment of advanced prostate cancer, most patients with metastatic spread will ultimately die of progressive disease, and prostate cancer remains one of the leading causes of cancer-related deaths in men worldwide.1,2 Over the last decade, there has been an increasing understanding of mechanisms of disease progression after androgen deprivation therapy, which has led to the development of multiple new androgen receptor (AR)-directed drugs with promising activity for patients with metastatic castration-resistant prostate cancer (mCRPC).3–5 Of those, abiraterone (an oral CYP17 inhibitor), and enzalutamide (an oral AR-antagonist), have demonstrated significant clinical activity and have been approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) based on notable improvements in median overall survival (OS), radiographic progression-free survival (rPFS), and quality of life.6,7 Nonetheless, these trials also demonstrate that about 10% to 20% of all patients with mCRPC show primary resistance to abiraterone or enzalutamide, and most of the remaining patients who have an initial clinical benefit will eventually develop disease progression later.8–11 Since patients progressing on abiraterone or enzalutamide often present with a rising PSA, it has become evident that many resistance mechanisms are related to persistent androgen/AR

Major advances have been achieved recently in the treatment of metastatic castration-resistant prostate cancer, resulting in significant improvements in quality of life and survival with the use of several new agents, including the next-generation androgen receptor (AR)-targeted drugs abiraterone and enzalutamide. However, virtually all patients will eventually progress on these therapies and most will ultimately die of treatment-refractory metastatic disease. Recently, several mechanisms of resistance to AR-directed therapies have been uncovered, including the AR splice variant 7 (AR-V7), which is a ligand-independent constitutionally-active form of the AR that has been associated with poor outcomes to abiraterone and enzalutamide. Galeterone, a potent anti-androgen with three modes of action (CYP17 lyase inhibition, AR antagonism, and AR degradation), is a novel agent under clinical development that could potentially target both full-length AR and aberrant AR, including AR-V7. In this manuscript, we will first discuss the biological mechanisms of action of galeterone and then review the safety and efficacy data from Phase I and II clinical studies of galeterone in patients with metastatic castration-resistant prostate cancer. A Phase III study of galeterone (compared against enzalutamide) in AR-V7-positive patients is currently underway, and represents the first pivotal trial using a biomarker-selection design in this disease.

Keywords: galeterone, AR splice variants, AR-V7, castration-resistant prostate cancer

Introduction

Despite significant recent advances in the treatment of advanced prostate cancer, most patients with metastatic spread will ultimately die of progressive disease, and prostate cancer remains one of the leading causes of cancer-related deaths in men worldwide.1,2 Over the last decade, there has been an increasing understanding of mechanisms of disease progression after androgen deprivation therapy, which has led to the development of multiple new androgen receptor (AR)-directed drugs with promising activity for patients with metastatic castration-resistant prostate cancer (mCRPC).3–5 Of those, abiraterone (an oral CYP17 inhibitor), and enzalutamide (an oral AR-antagonist), have demonstrated significant clinical activity and have been approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) based on notable improvements in median overall survival (OS), radiographic progression-free survival (rPFS), and quality of life.6,7 Nonetheless, these trials also demonstrate that about 10% to 20% of all patients with mCRPC show primary resistance to abiraterone or enzalutamide, and most of the remaining patients who have an initial clinical benefit will eventually develop disease progression later.8–11 Since patients progressing on abiraterone or enzalutamide often present with a rising PSA, it has become evident that many resistance mechanisms are related to persistent androgen/AR...
signaling, including AR and CYP17 upregulation, activating AR mutations, AR splice variants, glucocorticoid-receptor upregulation, and others.\textsuperscript{12–20}

Among these, AR splicing variants have received a lot of attention recently. In particular, AR splice variant 7 (AR-V7) is a constitutionally-active variant of the AR that lacks the ligand-binding domain (LBD) and has emerged as an important mechanism of primary and acquired resistance to AR-targeted agents targeting the LBD of the AR.\textsuperscript{18,21} One potentially promising strategy would be to identify agents that could overcome this resistance mechanism by inhibiting the AR outside of the androgen-binding site. In this manuscript, we will review the preclinical and clinical data related to galeterone, a multi-targeted AR-signaling inhibitor for the treatment of CRPC.

**Overview of approved agents for CRPC**

Over the last decade, a major paradigm shift has been observed in the treatment of mCRPC, with approval of several new agents with different mechanisms of action, including cytotoxic chemotherapy (cabazitaxel) after docetaxel failure,\textsuperscript{22,23} next-generation AR-directed therapies (abiraterone and enzalutamide),\textsuperscript{8–11,24,25} an autologous immunotherapy agent (sipuleucel-T),\textsuperscript{26} and the α-emitting radiopharmaceutical radium-223.\textsuperscript{27} All of these approved agents have demonstrated significant clinical activity with OS improvement and benefits in several secondary endpoints included in each trial (Table 1). In daily medical practice, these agents continue to provide clinically meaningful benefits including pain relief and improvements in quality of life. The major challenge that clinicians face when treating patients with mCRPC is how to best sequence these agents in order to maximize benefits for an individual patient.\textsuperscript{28–30} Currently, oncologists often use clinical parameters such as pathology, symptoms, volume and location of metastasis, and proportion of PSA level to disease volume to help define the most appropriate agent to be used, since there are no predictive biomarkers to date that help in selecting the best treatment strategy.\textsuperscript{29} Many trials are currently underway evaluating different treatment sequences as well as various drug combinations in order to maximize outcomes.\textsuperscript{30} Hopefully in the future, with a better understanding of the mechanisms of drug resistance and response, predictive biomarkers will be identified to determine the use of agents most likely to benefit each patient (ie, treatment-selection biomarkers).

**Mechanisms of resistance to AR-directed therapies**

Despite the significant success achieved with the next-generation AR-directed therapies, eventually all patients will progress despite these therapies and will ultimately die of progressive metastatic disease. Therefore, it is key to uncover these mechanisms to allow the development of newer and more active agents, which could overcome the known resistance mechanisms. In addition, this could aid in the development of predictive biomarkers that could aid in treatment selection choices. Several mechanisms of resistance to AR-directed therapies have been described, and broadly divided into 1) AR-dependent mechanisms and 2) AR-independent mechanisms.

**AR-dependent mechanisms of resistance**

The main AR-dependent mechanisms of therapeutic resistance include CYP17 and AR upregulation, AR splice variants, activating AR mutations, and GR upregulation

### Table 1 Phase III clinical trials of FDA-approved drugs for metastatic castration-resistant prostate cancer

<table>
<thead>
<tr>
<th>Study</th>
<th>Year</th>
<th>Indication</th>
<th>N</th>
<th>PSA\textsubscript{50} decline\textsuperscript{a}</th>
<th>SRE benefit</th>
<th>Quality of life</th>
<th>mPFS (months)</th>
<th>Overall survival (months)</th>
<th>HR</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Docetaxel vs mitoxantrone\textsuperscript{a,b}</td>
<td>2004</td>
<td>1st line chemo</td>
<td>1,006</td>
<td>45% vs 32%</td>
<td>NA</td>
<td>Yes</td>
<td>NS</td>
<td>18.9 vs 16.5</td>
<td>0.76</td>
<td>0.009</td>
</tr>
<tr>
<td>Cabazitaxel vs mitoxantrone\textsuperscript{c}</td>
<td>2010</td>
<td>Post-docetaxel</td>
<td>755</td>
<td>39% vs 18%</td>
<td>NA</td>
<td>NA</td>
<td>2.8 vs 1.4</td>
<td>15.1 vs 12.7</td>
<td>0.70</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Sipuleucel-T vs placebo\textsuperscript{d}</td>
<td>2010</td>
<td>Pre- and post-docetaxel</td>
<td>512</td>
<td>2.6% vs 1.3%</td>
<td>NA</td>
<td>NA</td>
<td>3.7 vs 3.6</td>
<td>25.8 vs 21.7</td>
<td>0.78</td>
<td>0.03</td>
</tr>
<tr>
<td>Abiraterone vs placebo\textsuperscript{e}</td>
<td>2011</td>
<td>Post-docetaxel</td>
<td>1,195</td>
<td>29% vs 6%</td>
<td>Yes</td>
<td>Yes</td>
<td>5.6 vs 3.6</td>
<td>14.8 vs 10.9</td>
<td>0.65</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Abiraterone vs placebo\textsuperscript{f}</td>
<td>2012</td>
<td>Pre-docetaxel</td>
<td>1,088</td>
<td>62% vs 24%</td>
<td>NA</td>
<td>Yes</td>
<td>16.5 vs 8.3</td>
<td>34.7 vs 30.3</td>
<td>0.81</td>
<td>0.0033</td>
</tr>
<tr>
<td>Enzalutamide vs placebo\textsuperscript{g}</td>
<td>2012</td>
<td>Post-docetaxel</td>
<td>1,199</td>
<td>54% vs 2%</td>
<td>Yes</td>
<td>Yes</td>
<td>8.3 vs 2.9\textsuperscript{h}</td>
<td>18.4 vs 13.6</td>
<td>0.63</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Radium-223 vs placebo\textsuperscript{i}</td>
<td>2013</td>
<td>Pre- and post-docetaxel\textsuperscript{i}</td>
<td>921</td>
<td>16% vs 6%</td>
<td>Yes</td>
<td>Yes</td>
<td>3.6 vs 3.4\textsuperscript{j}</td>
<td>14.9 vs 11.3</td>
<td>0.70</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Enzalutamide vs placebo\textsuperscript{11}</td>
<td>2014</td>
<td>Pre-docetaxel</td>
<td>1,717</td>
<td>78% vs 3%</td>
<td>Yes</td>
<td>Yes</td>
<td>NR vs 3.9\textsuperscript{k}</td>
<td>NR vs 31.0</td>
<td>0.73</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

**Notes:** \textsuperscript{a} Defined as PSA reduction $\geq$ 50%; \textsuperscript{b} prednisone was included in both experimental and control arms; \textsuperscript{c} radiographic progression-free survival; \textsuperscript{d} both arms received best standard of care; \textsuperscript{e} post-docetaxel or not candidates for docetaxel; \textsuperscript{f} PSA reduction $\geq$ 30%; \textsuperscript{g} time to PSA progression.

**Abbreviations:** N, number of patients; SRE, skeletal related events; mPFS, median progression-free survival; chemo, chemotherapy; NS, non-significant; NA, not assessed; NR, not reached; PSA, prostate specific antigen; FDA, US Food and Drug Administration; HR, hazard ratio.
Ultimately, these mechanisms will allow AR nuclear translocation and activation of nuclear transcriptional programs, or activation of androgen-response elements by alternative steroid receptors, leading to proliferation and disease progression despite testosterone-depleting agents (eg, androgen deprivation, abiraterone) or AR antagonists (eg, enzalutamide, apalutamide).

The role of CYP17 and AR overexpression was demonstrated by three studies with similar designs conducted by Efstathiou et al. In these studies, patients treated with abiraterone, enzalutamide, or both underwent transiliac bone marrow biopsies: AR and CYP17 expression was assessed by immunohistochemistry. A pre-treatment androgen-signaling signature was proposed based on CYP17 expression ([-]>10%) and AR N-terminal domain expression ([+++] >75%), which predicted benefit with AR-directed therapies in these studies. Moreover, in two of these studies, the presence of AR-V7 was assessed by immunohistochemistry at baseline, and was associated with primary resistance to enzalutamide or the combination of abiraterone and enzalutamide.

One potential predictive biomarker for resistance to the currently approved AR-directed therapies is the AR splice variants, particularly AR-V7, which is a constitutionally active form of the AR that lacks the LBD, the target of enzalutamide and abiraterone. Amongst the AR splice variants (22 have been described to date), AR-V7 is the most prevalent and its expression increases about 20-fold in the setting of AR-full length (FL) suppression by castration, suggesting that AR-V7 is biologically important and may be associated with ligand-independent AR-dependent progression of disease. The clinical importance of AR-V7 in the setting of treatment with AR-directed agents was demonstrated in a recent pilot study of patients with mCRPC treated with abiraterone or enzalutamide. In this prospective study, AR-V7 status was determined by a circulating tumor cell (CTC)-based real-time polymerase chain reaction (RT-PCR) assay in 62 patients and was associated with clinical outcomes for abiraterone (n=31) or enzalutamide (n=31). In both cohorts, the rate of PSA decline ≥50% (PSA <0.2 ng/mL) was high in the AR-V7 negative patients (52.6% and 68% for enzalutamide and abiraterone, respectively), but no AR-V7-positive patients achieved a PSA <0.2 ng/mL response. Moreover, in both cohorts, the AR-V7-negative group demonstrated a significantly higher disease-free survival and OS. Although these results are preliminary and need to be validated in larger prospective studies, the preclinical rationale and the magnitude of results observed strongly suggest that patients with AR-V7-positive CTCs may show primary resistance to abiraterone and enzalutamide. In addition, the CTC-based assay for AR-V7 detection requires further biomarker validation before incorporation into clinical practice. One notable finding is that the AR-V7 status was not associated with resistance to taxane-based chemotherapy in recent studies, highlighting the importance of this biomarker for future treatment selection for patients with CRPC if these results are confirmed. Preliminary data on patients with serial “liquid biopsies” for CTC-based AR-V7 analysis suggest that some patients develop AR-V7 CTCs upon disease progression and in some patients the AR-V7 status may be converted from positive to negative when treated with taxane-based chemotherapy. The clinical significance of this remains unknown.

AR point mutations are another mechanism of resistance increasingly being described, particularly in the setting of acquired resistance to abiraterone and next-generation AR antagonists (enzalutamide and apalutamide). The AR mutations described may convert these AR-antagonists into pure agonists (AR F877L), or may allow the AR to be activated by progesterone (AR T878A) or glucocorticoids (AR L702H) in abiraterone/prednisone-treated patients. These studies have shown that the presence of these activating mutations in AR are associated with inferior PFS and OS outcomes compared to men that harbor neither mutated nor amplified AR.

Therefore, targeting the AR-V7 and activating AR mutations is an area of priority for development of novel therapies to overcome resistance to drugs targeting the LBD of the AR, such as abiraterone, enzalutamide, and even newer drugs currently being tested in clinical trials such as apalutamide (ARN-509) and ODM-201. Some of these resistance mechanisms may perhaps be overcome with the use of galeterone, which has the ability to degrade various forms of the AR at the protein level.

AR-independent mechanisms of resistance

The AR-independent mechanisms of resistance have been increasingly recognized over the past few years due to a significant proportion of patients progressing after more active AR-directed drugs such as abiraterone and enzalutamide, often with a very aggressive clinical phenotype, described as anaplastic/small cell variant, characterized by a low PSA, osteolytic bone metastasis, visceral disease, refractoriness to available therapies, and short survival. In addition, intermediate phenotypes (such as the recently coined histology: intermediate atypical carcinoma) can
be recognized in patients progressing after multiple lines of hormonal therapy. These patients often develop AR-independent mechanisms of resistance, including activation of PI3K/AKT pathway (often resulting from PTEN loss), Rb loss, inactivating TP53 mutations, expression of AURKA and N-Myc, alteration in DNA-repair genes, among others. Currently, several strategies are being developed to target these alterations and more comprehensive reviews on this topic can be found elsewhere. \(^ {45-48} \)

**Galeterone: evidence to date**

Preclinical studies

During the effort to identify potent CYP17 inhibitors in the 1990s and 2000s, 3β-(hydroxy)-17-(1H-benzimidazole-1-yl) androstane-5,16-dione (galeterone, formerly TOK-001 or VN/124-1) was identified as a multi-targeted AR inhibitor candidate. Initially identified as a potent CYP17 inhibitor, multiple subsequent preclinical studies have demonstrated that galeterone also acts as an AR antagonist to both FL and mutant AR, in addition to its ability to degrade the AR, including AR splice variants (Figure 1). \(^ {49-54} \) It has also been demonstrated that galeterone inhibits enzalutamide-resistant cells in vitro, and also blocks AR nuclear translocation and activation of androgen-dependent genes such as PSA and TMPRSS2. \(^ {55} \) The discovery, chemical properties and preclinical development of galeterone have been comprehensively reviewed elsewhere, \(^ {56} \) although the current understanding of its degradation of AR will be reviewed briefly here.

**AR degradation**

One of the described mechanisms of AR regulation involves the E3 ubiquitin ligase pathway. \(^ {57,58} \) It has been described that the AR, MDM2, and AKT form a complex in vivo that results in ubiquitination and proteasome degradation of the AR. Specifically, it is thought that AKT phosphorylates MDM2 and the AR itself leading to MDM2 binding to the AR as a required step for AR degradation, and it has been shown that specific MDM2 binding site mutations inhibit

---

**Figure 1** Three mechanisms of action of galeterone.

**Notes:** This figure highlights the androgen receptor (AR) activation axis, with conversion of testosterone to dihydrotestosterone (DHT) by the 5α-reductase enzyme, and subsequent AR activation, dimerization, nuclear translocation and activation of transcriptional activation of target genes. The figure also demonstrates potential mechanisms of resistance to AR therapies, including the development of AR splice variants (AR-V) and AR mutations. Finally, it highlights galeterone’s mechanisms of action in each of these AR signaling pathways implicated in resistance to novel androgen/AR-directed therapies: 1) CYP lyase inhibition; 2) AR antagonism to both full-length and mutant AR; and 3) degradation of the AR, including AR splice variants.

**Abbreviation:** Enz, enzalutamide.
AR ubiquitination and degradation. In addition, other E3 ubiquitin ligases are probably involved in the AR regulation process, such as CHIP and SKP2 which also promote AR degradation, and Siah2, RNF6, and USP12 which promote deubiquitination and AR activation. To this end, it has been shown that galeterone-induced AR degradation is blocked by co-administration of proteasome inhibitors and also by E3 ligases MDM2 and CHIP selective knockdown, suggesting that galeterone disrupts the AR through proteasome degradation. Notably, a recent study that screened a panel with 22 deubiquitinating enzymes in vitro showed that galeterone inhibits the enzymatic activity of USP12 and also binds directly to the USP12 and USP12/UAf1 complexes, which dephosphorylate AKT. Therefore, the summation of data suggests that galeterone induces AR proteasomal degradation through the E3 ubiquitin ligase pathway, by changing the balance between ubiquitination and deubiquitination, both with respect to the FL AR and AR splice variants.

**Clinical studies: ARMOR1 and ARMOR2**

The Androgen Receptor Modulation Optimized for Response (ARMOR) Phase I and Phase II studies conducted with galeterone were recently published and demonstrated that galeterone is a well tolerated drug with promising clinical activity for patients with CRPC. Table 2 summarizes the main characteristics and outcomes of the ARMOR trials.

The Phase I ARMOR1 trial included 49 patients with progressive CRPC, including patients with metastatic (M₁) and non-metastatic (M₀) disease, and excluded patients who had previously received taxane chemotherapy, ketoconazole, abiraterone, or enzalutamide. This was a multicenter, dose-escalation study, which included eight dose-cohorts to assess the tolerability, safety, and efficacy of oral galeterone capsules (micronized powder, 325 mg), with dose-levels ranging from 650 mg to 2,600 mg daily. After a healthy volunteer study demonstrated a significant food effect with the capsule formulation used in the ARMOR1 study, a new formulation with no food effect – the galeterone spray dry dispersion (SDD) – was developed and was included in the dose-escalation component of the Phase II trial of galeterone in CRPC (ARMOR2, part 1). This Phase II study included 28 patients in three dosing cohorts using the 425 mg SDD tablets (1,700 mg, 2,550 mg and 3,400 mg daily) and allowed inclusion of abiraterone-resistant patients. Results of the healthy volunteer study also demonstrated equivalent serum concentrations using either 2,600 mg capsules or 1,700 mg SDD tablet formulations. Therefore, the ARMOR2, part 1 trial was designed to evaluate the safety of escalating doses of galeterone in the SDD tablet formulation to determine the recommended dose for the Phase II ARMOR2, part 2 and Phase III (ARMOR3-SV) trials.

In ARMOR1 and ARMOR2 part 1, 12/49 and 6/28 patients discontinued galeterone therapy before 12 weeks due to treatment-related adverse events (AEs). In these trials, 21 and 19 patients were eligible for the expansion phase of ARMOR1 and ARMOR2 part 1, respectively. Overall the treatment was well tolerated in this case and, although most patients in both studies experienced at least one AE, no action was required in most cases. The most common treatment-related AEs were nausea, pruritus, fatigue, anorexia, diarrhea, and increased ALT levels (Table 3). Of note, no apparent mineralocorticoid excess syndrome was observed despite concomitant corticosteroid use not being required. In terms of overall clinical activity across all dose levels, 22% and 48% of patients achieved PSA decline in ARMOR1 and ARMOR2 part 1, respectively. In the 2,550 mg dose cohort of ARMOR2 part 1, 72.7% and 54.5% achieved a PSA decline ≥30% and ≥50%, respectively. The pharmacokinetic results of this study demonstrated that there was no increase in plasma exposure to doses higher than 2,550 mg, which was the recommended dose for subsequent Phase II and Phase III trials based on pharmacokinetics, safety, and PSA response data.

ARMOR2 part 2 is an ongoing study designed to assess the safety and efficacy of the 2,550 mg SDD tablet formulation of galeterone once a day in four distinct mCRPC cohorts: non-metastatic treatment-naïve (TN) CRPC (M₀-TN,

---

**Table 2 Main characteristics and outcomes of the ARMOR1 and ARMOR2 clinical trials**

<table>
<thead>
<tr>
<th></th>
<th>ARMOR1</th>
<th>ARMOR2, part 1</th>
<th>ARMOR2, parts 1 and 2 (combined study)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of patients</td>
<td>49</td>
<td>28</td>
<td>107</td>
</tr>
<tr>
<td>Metastatic disease (M₁)</td>
<td>51%</td>
<td>86%</td>
<td>77%</td>
</tr>
<tr>
<td>Abi-R or Enz-R patients</td>
<td>No</td>
<td>Abi-R: three patients</td>
<td>Abi-R: 37 patients</td>
</tr>
<tr>
<td></td>
<td></td>
<td>SDD tablets</td>
<td>Enz-R: nine patients</td>
</tr>
<tr>
<td>Drug formulation</td>
<td>Capsules</td>
<td></td>
<td>SDD tablets</td>
</tr>
<tr>
<td>Food effect</td>
<td>Yes</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>Dose range</td>
<td>650 mg</td>
<td>1,700 mg</td>
<td>2,550 mg</td>
</tr>
<tr>
<td></td>
<td>975 mg</td>
<td>2,550 mg</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1,300 mg</td>
<td>3,400 mg</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1,950 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>2,600 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PSA decline ≥30%</td>
<td>49%</td>
<td>64%</td>
<td>83%</td>
</tr>
<tr>
<td>PSA&lt;sub&gt;A₀&lt;/sub&gt;</td>
<td>22.4%</td>
<td>48%</td>
<td>70%</td>
</tr>
</tbody>
</table>

**Note:** PSA decline results in the M₁ and M₀ treatment-naïve cohorts.

**Abbreviations:** Abi-R, abiraterone refractory; Enz-R, enzalutamide refractory; SDD, spray dry dispersion; PSA<sub>A₀</sub>, PSA decline ≥50%.
seven patients), metastatic TN CRPC (M₁-TN, 24 patients), abiraterone-refractory mCRPC (eleven patients), and enzalutamide-refractory mCRPC (two patients).° Preliminary results of the first three patient cohorts were presented at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting and demonstrated significant clinical activity with PSA declines of ≥30% and ≥50% in 83% and 67% in the M₀-TN group, and 92% and 83% in the M₁-TN cohort, respectively. Two out of five (40%) patients in the abiraterone-refractory cohort achieved a PSA decline ≥30%. In terms of toxicity, 94% of all AEs were grade 1 or 2 and the most common events were nausea, diarrhea, fatigue, and pruritus. No mineralocorticoid excess symptoms or seizures were recorded in the study.° These results were updated at the 2014 European Society of Medical Oncology (ESMO) meeting, with safety data of the 107 patients included and efficacy results demonstrating a PSA decline ≥30% and ≥50% in 83% and 70% of patients in the M₀ and M₁ TN cohorts, respectively (Table 4). In the abiraterone-refractory cohort, among the 15 evaluable patients to date, 13% achieved a PSA decline ≥30% and 27% had some degree of PSA decline.°

In an exploratory analysis of circulating tumor cells in patients included in the ARMOR2 trial, 90% (64/71) of enrolled patients had ≥1 CTC detected.° In the M₀ and M₁ cohorts, the C-terminal AR immunohistochemical assay using the Epic Sciences platform was performed and seven of these patients were found to have AR C-terminal loss, implying the presence of AR splice variants (perhaps including AR-V7 as well as others). Notably, six of these seven patients (86%) with C-terminal loss achieved a PSA$_{\text{VR}}$ suggesting that galeterone may be active in patients harboring AR splice variants (eg, AR-V7). Four patients continued on galeterone in the optional extension phase, with time on treatment ranging from 155 to >334 days. Another interesting finding suggests that post-galeterone therapies with docetaxel or other AR-directed therapies (such as abiraterone and enzalutamide) may confer PSA declines, although this retrospective analysis included only nine patients, five of whom had discontinued galeterone due to AEs.°

Table 3 Main adverse events in the ARMOR1 and ARMOR2 clinical trials

<table>
<thead>
<tr>
<th>Main grade 1 or 2 AEs$^a$</th>
<th>ARMOR1$^a$</th>
<th>ARMOR2, part I$^a$</th>
<th>ARMOR2, parts I and 2 (combined study)$^a$</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fatigue</td>
<td>16 (32.7%)</td>
<td>9 (32.1%)</td>
<td>35 (32.7%)</td>
</tr>
<tr>
<td>Nausea</td>
<td>12 (24.5%)</td>
<td>13 (46.4%)</td>
<td>36 (33.6%)</td>
</tr>
<tr>
<td>Vomiting</td>
<td>6 (12.2%)</td>
<td>8 (28.6%)</td>
<td>13 (12.1%)</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>11 (22.4%)</td>
<td>4 (14.3%)</td>
<td>17 (15.9%)</td>
</tr>
<tr>
<td>Decreased appetite</td>
<td>6 (12.2%)</td>
<td>6 (21.4%)</td>
<td>22 (20.6%)</td>
</tr>
<tr>
<td>Pruritus</td>
<td>11 (22.4%)</td>
<td>9 (32.1%)</td>
<td>28 (26.2%)</td>
</tr>
<tr>
<td>Increased AST level</td>
<td>13 (26.5%)</td>
<td>1 (3.6%)</td>
<td>9 (8.4%)</td>
</tr>
</tbody>
</table>

All grade ≥3 AEs$^b$

| Increased ALT level      | 8 (16.3%) | 3 (10.7%) | 5 (4.7%) |
| Increased AST level      | 3 (6.1%)  | 1 (3.6%)  | 2 (1.9%) |
| Increased bilirubin      | 1 (2%)    | 0         | 1 (<1%)  |
| Constipation             | 0         | 1 (3.6%)  | 0        |
| Diarrhea                 | 0         | 1 (3.6%)  | 1 (<1%)  |
| Fatigue                  | 1 (2%)    | 0         | 3 (2.8%) |
| Rash                     | 0         | 1 (3.6%)  | 1 (<1%)  |
| Pruritus                 | 0         | 0         | 4 (3.7%) |
| Hypokalemia              | NR        | NR        | 3 (2.8%) |
| Hypertension             | NR        | NR        | 2 (1.9%) |

Notes: $^a$Adverse events that occurred in ≥20% of patients in any cohort; $^b$grade ≥3 adverse events that occurred in >1% of patients in any cohort.

Abbreviations: AEs, adverse events; NR, not reported; ALT, alanine aminotransferase; AST, aspartate aminotransferase.

Table 4 ARMOR2: galeterone efficacy summary

<table>
<thead>
<tr>
<th>Cohort</th>
<th>Number of patients</th>
<th>Any PSA decline</th>
<th>Best response by PCWG2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-metastatic (M₀-TN) mCRPC</td>
<td>21</td>
<td>21 (100%)</td>
<td>No evidence of metastasis at 12 weeks</td>
</tr>
<tr>
<td>Metastatic (M₁-TN) mCRPC</td>
<td>39</td>
<td>35 (90%)</td>
<td>Stable disease: 75%</td>
</tr>
<tr>
<td>Abi-R mCRPC</td>
<td>30</td>
<td>11 (37%)</td>
<td>Stable disease: 47%</td>
</tr>
<tr>
<td>Enz-R mCRPC</td>
<td>9</td>
<td>4 (44%)</td>
<td>Stable disease: 57%</td>
</tr>
</tbody>
</table>

Note: Data from Taplin et al.°°

Abbreviations: mCRPC, metastatic castration-resistant prostate cancer; TN, treatment-naïve; Abi-R, abiraterone refractory; Enz-R, enzalutamide refractory; PCWG2 Prostate Cancer Working Group 2; PSA, prostate specific antigen.
develop confirmed radiographic progression of their disease (according to Prostate Cancer Working Group 2 criteria), or if they develop unmanageable toxicity. The primary endpoint of ARMR3-SV is rPFS, with OS being the key secondary endpoint. Enrollment is expected to finish in early 2017, and primary results on the rPFS endpoint are expected by late 2017. If successful, this trial would be the first study to result in drug approval using an rPFS endpoint, and the first trial to employ a biomarker-selection design in prostate cancer. Moreover, if this trial demonstrates a superiority of galeterone over enzalutamide, it could represent a new option for patients with disease progression after available therapies who develop AR-V7 positive CTCs during the course of their disease.

**Perspectives**

Despite the many advances achieved thus far in the understanding of the biology of mCRPC, it is clear that with more active AR-directed drugs the complexity of the mechanisms of resistance and progression is increasing, and novel approaches are needed to improve patient outcomes. Galeterone is a unique AR-directed drug with multiple mechanisms of action including CYP17 inhibition while also acting as an AR antagonist and AR degrader. Therefore, galeterone could potentially overcome aberrant AR signaling mediated by mutant-activated AR as well as constitutively-active AR splice variants, which have been recognized as potential escape mechanisms to abiraterone and enzalutamide, by virtue of its protein degradation mechanism. It should be highlighted that galeterone will not address the non-AR-dependent mechanisms of castration-resistance.

In order to evaluate galeterone’s efficacy for AR-V7 positive patients, the first biomarker-driven Phase III randomized trial in mCRPC (Figure 2; ARMR3-SV, NCT02438007) has been launched and will compare the efficacy of galeterone against enzalutamide in mCRPC patients harboring AR-V7, and hopefully will demonstrate activity in this refractory patient population. Meanwhile, additional Phase II trials are being planned using galeterone in the post-abiraterone and post-enzalutamide populations. Finally, if galeterone is truly capable of targeting and degrading AR-V7 and other splice variants, it remains possible that this agent may theoretically sensitize (or even re-sensitize) CRPC patients to treatment with abiraterone and enzalutamide, although this hypothesis remains to be tested.

**Acknowledgment**

ESA has received funding from the Prostate Cancer Foundation, the Patrick C. Walsh Fund, and NIH grants R01 CA185297 and P30 CA006973.

**Disclosure**

ESA has served as a paid consultant/advisor for Janssen, Astellas, Sanofi, Dendreon, Merck, Essa, and Medivation; has received research funding to his institution from Janssen, Johnson & Johnson, Medivation, Sanofi, Dendreon, Bristol Myers Squibb, Genentech, Novartis, Bayer and Tokai; and is a co-inventor of a biomarker technology that has been licensed to Tokai. DAB declares no conflicts of interest in this work.

**References**

2296


